An Introduction to Allergic Diseases
The incidence of respiratory allergies is increasing, particularly in industrialized areas. Allergic inflammation can occur in both the upper and lower airways, and can differ substantially in intensity. Traditional drug therapy such as antihistamines, corticosteroids, anticholinergic agents and leukotriene inhibitors is important in reducing and preventing symptoms and is essential in acute use. More recent therapies including anti-immunoglobin E (IgE) therapy, anti-interleukin (IL) monoclonal antibodies, and phosphodiesterase 4/phospholipaseA2 inhibitors, have improved outcomes. However, in order to develop more effective therapies, further research is needed into the molecular mechanisms underlying respiratory allergy onset, particularly in terms of intracellular reactions and the cytosolic Ca2+ balance.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]
Isaac Schmale, AAAAI 2023: Signs and symptoms of aspirin-exacerbated respiratory disease and its treatment paradigm
touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]
Management of severe paediatric asthma: From hospital to home
Members of the MDT and a patient advocate discuss the optimal management of severe asthma in children
- Recall the diagnostic workup for severe type 2 asthma in children
- Explain the pathophysiology of severe type 2 asthma and how this can guide treatment decisions
- Discuss the importance of the MDT in optimizing the management of children with severe asthma
What’s new for eosinophilic oesophagitis? A case-based discussion of patient care
Watch experts give their perspective on different aspects of managing patients with EoE, based on clinical case studies.
- Describe the complex pathophysiology of EoE and how this manifests as clinical symptoms throughout life
- Distinguish eosinophilic oesophagitis as a progressive disease that is distinct from GORD
- Summarize the clinical evidence supporting the use of emerging biologic treatments for EoE
The practicalities of eosinophilic oesophagitis management: A closer look at emerging biologic treatment options
Watch leading experts discuss practical aspects of caring for children and adults with EoE, drawing on their own clinical experiences.
- Compare the pathophysiology and clinical manifestations of EoE between children and adults
- Summarize how the transition of care is managed as children with EoE become adults
- Evaluate the impact of the latest data for emerging biologic treatment options for EoE on clinical practice
The Role of Gefapixant in the Management of Chronic Cough
touchREVIEWS in Respiratory & Pulmonary Diseases. 2022;7(1):15–20
With the advent of newer drugs targeting the biochemical pathways that lead to cough, it is increasingly important to understand the definition, pathogenesis and management of this symptom. Several specialist bodies also recognize the need for guidance in this area, and the American College of Chest Physicians (ACCP) and European Respiratory Society (ERS) have both […]
Ozge Can Bostan, EAACI 2022: Low Dose Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
Mepolizumab is currently approved for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300mg. touchRESPIRATORY caught up with Dr. Ozge Can Bostan (Hacettepe University School of Medicine, Ankara, Turkey) to discuss the 1 year findings from her study investigating the sinonasal and respiratory outcomes of a low dose of mepolizumab (100 […]
Exploring eosinophilic oesophagitis: How can multidisciplinary management improve outcomes?
Watch leading specialists involved in the multidisciplinary care of patients with eosinophilic oesophagitis address the optimal management of this disorder.
- Explain how the complex pathophysiology of eosinophilic oesophagitis (EoE) impacts diagnosis
- Assess the symptoms associated with EoE and the impact of this progressive disease on patients
- Evaluate how the emerging biologic treatment options for EoE may be incorporated into clinical practice
Improving outcomes for patients with eosinophilic oesophagitis: What do the data from AAAAI 2022 tell us?
Watch this two-part activity exploring recent data on eosinophilic oesophagitis from the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) 2022. Part 1: Watch leading gastroenterologist, Dr Evan Dellon, review key data from AAAAI 2022 Watch now Part 2: Hear from three leading experts in eosinophilic oesophagitis, as they discuss what these data may mean for global and regional practice Select an interview
- Summarize recent clinical evidence on the complex pathophysiology and manifestations of eosinophilic oesophagitis (EoE)
- Outline the chronic nature of EoE and the impact on patient quality of life
- Assess the latest data for emerging treatments for EoE and their impact on clinical practice
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!